Related Experiment Videos
Pharmacokinetics of morphine infusion in premature neonates
Insights
This study on premature neonates found that higher doses of morphine did not offer clinical benefits and were well tolerated. Standard morphine dosing is recommended for neonates.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Clinical Pharmacy
Background:
- Premature neonates require careful pain management.
- Morphine is commonly used for analgesia in neonates.
- Understanding morphine pharmacokinetics in this population is crucial for safe and effective dosing.
Purpose of the Study:
- To investigate the pharmacokinetics of two different intravenous morphine dosing regimens in premature neonates.
- To assess the safety and tolerability of these morphine doses.
- To determine if higher morphine doses provide clinical advantages.
Main Methods:
- 17 premature neonates (26-34 weeks' gestation) received either standard or high-dose intravenous morphine infusions within 24 hours of birth.
- Plasma concentrations of morphine and its metabolites (M3G, M6G) were measured at 2 and 24 hours.
- Pharmacokinetic parameters including clearance, half-life, and volume of distribution were calculated.
Main Results:
- Higher morphine doses resulted in significantly higher plasma concentrations compared to standard doses.
- Morphine-3-glucuronide and Morphine-6-glucuronide were detected as major metabolites.
- High morphine concentrations were generally well tolerated, with transient muscle rigidity in two infants and no seizures.
- No statistically significant decrease in mean arterial blood pressure was observed.
Conclusions:
- The high-dose morphine regimen did not demonstrate clinical advantages over the standard dose.
- Standard dose morphine appears to be well-tolerated in premature neonates.
- Further research may be needed to optimize neonatal pain management strategies.
Abstract:
Morphine pharmacokinetics were studied in 17 premature neonates (26-34 weeks' gestation) after intravenous infusion during the first 24 hours of life. Infants received either standard dose morphine that comprised of a 100 micrograms/kg/hour loading infusion for 2 hours followed by a maintenance infusion of 12.5 micrograms/kg/hour, or a high dose of 200 micrograms/kg/hour for 2 hours followed by 50 micrograms/kg/hour. Mean plasma concentrations of morphine (SD) after 2 and 24 hours were 99 (12.9) and 96.4 (3.2) ng/ml, and 184.2 (37.7) and 319 (71.2) ng/ml for the standard and high dose regimens, respectively. Morphine-3-glucuronide plasma concentrations achieved about 20% and 80% of morphine values at 2 and 24 hours respectively. Morphine-6-glucuronide could not be detected at 2 hours, but attained 20-25% of morphine plasma concentrations by 24 hours. The population mean morphine clearance was 2.4 ml/min/kg, the elimination half life was 8.75 hours and the volume of distribution was 1.82 1/kg. High plasma concentrations of morphine appeared to be well tolerated. Although mean arterial blood pressure decreased during the first six hours of treatment, this was not statistically significant; two infants experienced transient muscle rigidity, but no evidence of seizures was noted. There appears to be no clinical advantage in using the high dose regimen.